logo

HITAP เข้าสู่ระบบ

ลืมรหัสผ่าน?

Economic evaluation of HLA-B*1502 genotyping in Carbamazepine induced Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)

Home > Research Projects > Strategy 3 : HTA Research > Economic evaluation of HLA-B*1502 genotyping in Carbamazepine induced Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)

Project Code

11-303-2554(7)

Research team

Researchers

Tanunya Koopitakkajorn, B. (Pharm), M.Sc. (Pharm)

Waranya Rattanavipapong

Co - Researcher

Naiyana Praditsitthikorn, PhD.

Yot Teerawattananon, PhD.

Surakameth Mahasirimongkol

Project Details

Strategies
Category
Support
Tags
Project duration

Start: - May 2011
End: - April 2012

Contact
[email protected]

Project Status

Completed - 100%

Viewer: 2357

Publish date14 December 2011 12:26

Project Summary

Economic evaluation of HLA-B*1502 screening for preventing carbamazepine- induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) is prioritized by stakeholders under ‘Research for development of health benefit package under universal coverage scheme’. The study carried out an evidence to inform the Subcommittee for Development of the Benefit Package and Service Delivery – the coverage decision authority responsible for issuing the recommendations on whether HLA-B*1502 screening should be offered to individuals who are eligible under the health benefit package of the Universal Coverage Scheme. This is a cost-utility analysis using decision tree and Markov models to estimate costs and health outcomes of providing HLA-B*1502 screening compared to i) the current practice in which patients received carbamazepine without HLA-B*1502 screening, and ii) not prescribing carbamazepine but alternative drugs. The incremental cost-effectiveness ratio of the universal HLA-B*1502 screening compared with the current practice was estimated at 130,000 Thai Baht per quality-adjusted life year (QALY) gained for patients with neuropathic pain and 222,000 Thai Baht per QALY gained for patients with epilepsy.  

Documents

Activity

Health Intervention and Technology Assessment Program Foundation
Head Office : 88/22 Moo 4, 6th Building, 6th Floor, Department of Health, Ministry of Public Health, Tiwanon Road, Taladkwan Subdistrict, Muang Nonthaburi District, Nonthaburi 11000, Thailand


Tel. : +662-590-4549, +662-590-4374-5
Fax : +662-590-4369
E-mail : [email protected]
Website : www.hitap.net


© Copyright - HITAP 2014
Top